BIOSYSS SUBMITS 510(K) FOR BIOWAVE BPM 1 NON-INVASIVE BLOOD PRESSURE
This article was originally published in The Gray Sheet
Executive Summary
BIOSYSS SUBMITS 510(K) FOR BIOWAVE BPM 1 NON-INVASIVE BLOOD PRESSURE monitoring system on Sept. 28, the firm announced Sept. 29. The device, according to the company, is the first non-invasive system to provide blood pressure readings on a continuous basis. The BioWave BPM 1 constantly records pulse waveform through piezoelectric sensors that are placed on the patient's wrist. The pattern of the pulse waveform is then analyzed "using complex signal-processing techniques and proprietary algorithms" and translated into blood pressure readings. The device's monitor displays a visual of the waveform as well as numeric readings of systolic, diastolic and mean blood pressure and pulse rate. The device was tested in three clinical trials "on more than 150 patients" at Brigham & Women's Hospital in Boston, Sarasota Memorial Hospital in Florida and New Hampshire Heart Institute in Manchester. BioWave BPM is Biosyss Corp.'s first product. Founded in 1989, the privately held company has raised $1.4 mil. in financing to date, primarily from physicians. The Braintree, Massachusetts firm also has a letter of agreement with the investment banking firm Adams, Harkness & Hill for another $4 mil. in private financing. The seven-person company is headed by Jeffrey Barnes, formerly a technical marketing manager for Hewlett-Packard.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.